Anticoagulation in COVID-19

Charlotte A Bradbury; Zoe  McQuilten

doi:10.1016/S0140-6736(21)02503-4

Anticoagulation in COVID-19

Charlotte A Bradbury^*, Zoe McQuilten

^*Corresponding author for this work

Bristol Medical School (THS)

Research output: Contribution to journal › Article (Academic Journal) › peer-review

17 Citations (Scopus)

39 Downloads (Pure)

Original language	English
Pages (from-to)	5-7
Number of pages	3
Journal	Lancet
Volume	399
Issue number	10319
Early online date	15 Dec 2021
DOIs	https://doi.org/10.1016/S0140-6736(21)02503-4
Publication status	Published - 1 Jan 2022

Bibliographical note

Funding Information:
ZM declares no competing interests. Related to the topic, CAB has received speaker's fees from Bayer for non-promotional education and conference funding from Bayer to present research data unrelated to rivaroxaban. Unrelated to the topic, CAB has received speaker's fees from Amgen, Bristol Myers Squibb/Pfizer Alliance, Janssen, Eli Lilly, and Novartis; support to attend conferences from Amgen and Novartis; and advisory fees from Ablynx, Bristol Myers Squibb/Pfizer Alliance, Lilly, Novartis, and Portola.

Access to Document

10.1016/S0140-6736(21)02503-4

Full-text PDF (author’s accepted manuscript)
This is the author accepted manuscript (AAM). The final published version (version of record) is available online via Elsevier at https://doi.org/10.1016/S0140-6736(21)02503-4 . Please refer to any applicable terms of use of the publisher.
Accepted author manuscript, 179 KBLicence: CC BY-NC-ND

Handle.net

Persistent link

Cite this

@article{6b358f634d8c421fbe68a728d06174e9,

title = "Anticoagulation in COVID-19",

author = "Bradbury, {Charlotte A} and Zoe McQuilten",

note = "Funding Information: ZM declares no competing interests. Related to the topic, CAB has received speaker's fees from Bayer for non-promotional education and conference funding from Bayer to present research data unrelated to rivaroxaban. Unrelated to the topic, CAB has received speaker's fees from Amgen, Bristol Myers Squibb/Pfizer Alliance, Janssen, Eli Lilly, and Novartis; support to attend conferences from Amgen and Novartis; and advisory fees from Ablynx, Bristol Myers Squibb/Pfizer Alliance, Lilly, Novartis, and Portola.",

year = "2022",

month = jan,

day = "1",

doi = "10.1016/S0140-6736(21)02503-4",

language = "English",

volume = "399",

pages = "5--7",

journal = "Lancet",

issn = "0140-6736",

publisher = "Lancet Publishing Group",

number = "10319",

}

TY - JOUR

T1 - Anticoagulation in COVID-19

AU - Bradbury, Charlotte A

AU - McQuilten, Zoe

N1 - Funding Information: ZM declares no competing interests. Related to the topic, CAB has received speaker's fees from Bayer for non-promotional education and conference funding from Bayer to present research data unrelated to rivaroxaban. Unrelated to the topic, CAB has received speaker's fees from Amgen, Bristol Myers Squibb/Pfizer Alliance, Janssen, Eli Lilly, and Novartis; support to attend conferences from Amgen and Novartis; and advisory fees from Ablynx, Bristol Myers Squibb/Pfizer Alliance, Lilly, Novartis, and Portola.

PY - 2022/1/1

Y1 - 2022/1/1

U2 - 10.1016/S0140-6736(21)02503-4

DO - 10.1016/S0140-6736(21)02503-4

M3 - Article (Academic Journal)

C2 - 34921757

SN - 0140-6736

VL - 399

SP - 5

EP - 7

JO - Lancet

JF - Lancet

IS - 10319

ER -